XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs UE 2343 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms XanADu
- Sponsors Actinogen Medical
- 05 Dec 2017 Last checked against ClinicalTrials.gov record.
- 29 Nov 2017 According to an Actinogen Medical media release, the full study is expected to include up to 174 patients, statistically valid conclusions on the efficacy of Xanamem in Alzheimer's disease are unlikely from these data. The company remains on track to enrol the final patient by the end of 2018, with top-line results due in April-June 2019.
- 29 Nov 2017 According to an Actinogen Medical media release, Fortyfour (44) patients have been enrolled and the first 6 patients have already completed the study. It is expected that the 50 patients included in the interim analysis should be enrolled into the trial before the end of 2017, and an interim efficacy and safety data from the trial are expected to be available in April-June 2018.